The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.
Protocol Amendment History
2 changes
criticalTrial status changed: Recruiting → Active, Not Recruiting2026-07-25